Intra-Cellular Therapies, Inc. (ITI) Company Profile

14:57 EDT 23rd March 2018 | BioPortfolio

Intra-Cellular Therapies, Inc. (ITI) is a biotechnology company developing novel therapeutics for the treatment of depression, schizophrenia, Alzheimer's and Parkinson's disease and other disorders of the Central Nervous System. Using IntraPath, its broad technology platform, ITI has identified nerve-signaling proteins, validated their roles in vivo and is currently using these proteins as targets for small molecule drugs. Commercializing the Nobel-prize winning research of Dr. Paul Greengard, ITI is uniquely positioned to develop novel therapies for neuropsychiatric and neurodegenerative disorders. With its broad expertise in the molecular basis of neurotransmitter and drug action, ITI is validating drug candidates for its internal drug discovery programs and for its pharmaceutical partners. Founded by Drs. Greengard, Sharon Mates and Allen Fienberg, ITI began operations in May 2002 and is headquartered in the Audubon Biomedical Science & Technology Park in New York City.


3960 Broadway
New York
New York
United States of America


Phone: 212.923.3344
Fax: 212.923.3388

News Articles [586 Associated News Articles listed on BioPortfolio]

Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia

NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disord...

Intra-Cellular gets positive FDA feedback on rolling NDA for schizophrenia drug

The FDA and Intra-Cellular Therapies have reached an agreement on the proposed content and timing of a rolling new drug appli -More- 

Investor Network: Intra-Cellular Therapies, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018, at 8:30 AM...

FDA fast-tracks Intra-Cellular's schizophrenia drug

Intra-Cellular Therapies' schizophrenia drug candidate lumateperone was granted fast-track designation by the FDA. -More- 

Intra-Cellular Therapies nets $162mm in FOPO

Intra-Cellular Therapies Inc. (neuronal signaling pathway-based psychiatric disorder therapeutics) netted $162mm through a public offering of 11.1mm common shares (including the overallotment) at $15....

Intra-Cellular Therapies Appoints New EVP, Chief Medical Officer

The new addition has over two decades of industry experience

Intra-Cellular Therapies' (ITCI) CEO Sharon Mates on Q4 2017 Results - Earnings Call Transcript

FDA Awards Fast Track Designation to Intra-Cellular Therapies\' Schizophrenia Drug

Lumateperone has potential to benefit patients suffering from a range of neuropsychiatric and neurodegenerative diseases

PubMed Articles [2209 Associated PubMed Articles listed on BioPortfolio]

Cellular Therapies in Orthopedics: Where Are We?

The orthopedic field has experienced several major practice-changing pivotal shifts in the past several decades, such as the invention and application of the arthroscope or the implementation and adva...

Adipose-derived cellular therapies in solid organ and vascularized-composite allotransplantation.

Controlling acute allograft rejection following vascularized composite allotransplantation requires strict adherence to courses of systemic immunosuppression. Discovering new methods to modulate the a...

Intra- and Intercellular Quality Control Mechanisms of Mitochondria.

Mitochondria function to generate ATP and also play important roles in cellular homeostasis, signaling, apoptosis, autophagy, and metabolism. The loss of mitochondrial function results in cell death a...

Viral-Cellular DNA Junctions as Molecular Markers for Assessing Intra-Tumor Heterogeneity in Cervical Cancer and for the Detection of Circulating Tumor DNA.

The development of cervical cancer is frequently accompanied by the integration of human papillomaviruses (HPV) DNA into the host genome. Viral-cellular junction sequences, which arise in consequence,...

Quercetin Inhibits Cell Migration and Invasion in Human Osteosarcoma Cells.

Osteosarcoma is a malignant tumor associated with high mortality; however, no effective therapies for the disease have been developed. Several studies have focused on elucidating the pathogenesis of o...

Clinical Trials [3205 Associated Clinical Trials listed on BioPortfolio]

Regenerative Cellular Therapies, Physiology, Pathology and Developmental Biology

This study aims to use tissue from deceased organ donors to investigate organ physiology, developmental biology, as well as the development of future regenerative cellular therapies. It wi...

Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate the...

Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase I trial is s...

Impact of Omega-3 Fatty Acids on Lactate

Pre- and intra-operative nutritional support in patient undergoing major surgery results in decreased morbidity and mortality. Studies investigating the role of omega-3 fatty acids in thes...

Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)

Dendritic cell-based cellular vaccine for tumor therapy has shown efficacy. This study is designed to perform a personalized clinical trial by first analyzing the expression of tumor assoc...

Companies [1172 Associated Companies listed on BioPortfolio]

Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. (ITI)

Intra-Cellular Therapies, Inc. (ITI) is a biotechnology company developing novel therapeutics for the treatment of depression, schizophrenia, Alzheimer's and Parkinson's disease and other disorders of...


Philadelphia-based Intracorp, a subsidiary of CIGNA Corporation, helps employers maximize their workers' compensation and disability benefits programs to enhance the well-being an...

Intra-Lock® International, Inc.

Intra-Lock® International Inc., headquartered in Boca Raton, Florida, USA, is a leading provider of innovative dental restoration solutions including a wide range of dental imp...

Aastrom Biosciences, Inc.

Founded in 1989 and with headquarters in Ann Arbor, Michigan, Aastrom Biosciences is dedicated to the development of stem cell treatments for critical cardiovascular diseases. Aastrom is currently e...

More Information about "Intra-Cellular Therapies, Inc. (ITI)" on BioPortfolio

We have published hundreds of Intra-Cellular Therapies, Inc. (ITI) news stories on BioPortfolio along with dozens of Intra-Cellular Therapies, Inc. (ITI) Clinical Trials and PubMed Articles about Intra-Cellular Therapies, Inc. (ITI) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Intra-Cellular Therapies, Inc. (ITI) Companies in our database. You can also find out about relevant Intra-Cellular Therapies, Inc. (ITI) Drugs and Medications on this site too.

Quick Search


Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Bipolar Disorders
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Over half of Bipolar cases develops before the age of 25. Bipolar ...

Corporate Database Quicklinks

Searches Linking to this Company Record